22Jan
Blog: Cooley’s 2020 Life Sciences M&A Year in Review
General Trends in Life Sciences M&A - If 2019 was the year of life sciences mega-deals, 2020 was the year of COVID-19, as the global pandemic permeated every aspect of the dealmaking landscape, with the life sciences sector being no exception. COVID-19 drove unprecedented levels of collaboration among biopharmaceutical companies seeking to develop a vaccine, leading to an accelerated research and development process that allowed not just one—but two—vaccines to be approved by the FDA in...
By:
Cooley LLP
Related
Government contractors received a treat for Halloween, as President Trump issued an Executive Order ...
Read More >
On August 9, 2019, the National Labor Relations Board (“NLRB”) announced proposed rules¹ to change...
Read More >
Neither rain nor sleet nor quarantine restrictions stop bid protests or our monthly roundup. Thus f...
Read More >
Technology dealmaking has continued apace in 2020 as M&A investors take advantage of the sector’s r...
Read More >
In yet another blow to the suffering movie theater industry, Warner Bros. announced on Thursday that...
Read More >
Bill 108, the More Homes, More Choice Act, received Royal Assent on June 6, 2019. The Act amended 13...
Read More >